针对化疗诱导的自适应信号电路,在胰腺癌中赋予了治疗脆弱性
Yohei Saito1, Yi Xiao1, Jun Yao1
1Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Cell discovery
|October 29, 2024
概括
涉及Yap1和Cox2的新化疗诱导电路驱动胰腺癌的抵抗力. 在癌症和筋膜瘤中与吉米西塔,他类药物和阿司匹林共同向这些药物显示出对晚期胰腺管腺癌 (PDAC) 治疗的前景.
科学领域:
- 在瘤学瘤学.
- 癌症生物学 癌症生物学
- 分子信号传输的方法
背景情况:
- 晚期胰腺管腺癌 (PDAC) 显示治疗反应不佳.
- 目前的治疗方法,包括化疗和免疫疗法,对于晚期PDAC基本上无效.
- 迫切需要新的治疗策略来克服PDAC的治疗耐药性.
研究的目的:
- 研究导致PDAC对治疗反应不佳的信号网络.
- 在这些网络中确定治疗干预的关键分子标.
- 评估在临床前模型和患者数据中共同准确定的途径的有效性.
主要方法:
- 从PDAC小鼠模型和临床患者数据中整合单细胞转录组数据.
- 鉴定Yap1 (癌细胞) 和Cox2 (流体纤维细胞) 作为化疗诱导的信号电路中的关键节点.
- 在PDAC小鼠模型中,对联合向Yap1和Cox2的临床前评估与gemcitabine结合.
- 对PDAC患者数据的回顾性分析,将治疗与生存结果关联起来.
主要成果:
- 鉴定了一种新的化疗诱导的共生信号电路,赋予化学抵抗,涉及癌细胞中的Yap1和 stromal 纤维细胞中的Cox2.
- 在癌细胞和肌层中同时准Yap1和Cox2,使PDAC对gemcitabine敏感,显著延长小鼠的存活时间.
- 在患者数据中,与显著改善的生存相关联的患者数据中,与gemcitabine一起抑制Yap1 (例如,他类药物) 和Cox2 (例如,阿司匹林).
结论:
- 化疗诱导了PDAC中的一个适应性抵抗电路,涉及Yap1和Cox2.
- 在瘤细胞和瘤层中共同准这种电路代表了对先进PDAC的有希望的治疗策略.
- 类药物和阿司匹林,结合化疗,为PDAC患者提供了潜在的新型治疗方法.
相关概念视频
01:19Interactions Between Signaling Pathways
6.2K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.2K
02:53Adaptive Mechanisms in Cancer Cells
5.7K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K
03:03mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
01:31The Intrinsic Apoptotic Pathway
6.4K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.4K
01:17Intracellular Signaling Affects Focal Adhesions
2.6K
Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
Some...
2.6K